Global Renal Cell Carcinoma Drugs Market 2020
Renal cell carcinoma, also called renal adenocarcinoma, is a disease in which malignant or cancerous cells are found in the lining of tubules in the kidney. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. Various tests, like ultrasound, urine analysis, intravenous pyelogram, CT scan, MRI and biopsy, are available now-a-days that can help in early diagnosis of this disease. The drugs which are used for the treatment of the renal cell carcinoma include the likes of Sutent, Votrient, Inlyta and Nexavar among others. The latest addition to this lot is Opdivo by Bristol-Myers Squibb. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.
According to the report “Global Renal Cell Carcinoma Drugs Market 2020”, the renal cell carcinoma drugs market is anticipated to cross US$ 4 Billion by 2020. The report provides a detailed analysis of the market for these drugs. The report provides the current and forecasted market for renal cell carcinoma drugs.
Moreover, the report provides information and revenues of the major branded drugs in the market for this disease. The segmentation of renal cell carcinoma drugs market has been done in the report on the basis of different geographical regions. North America is accounted for the largest share of the renal cell carcinoma market. This high share was attributed to colossal patient pool, large number of commercially available drugs for the treatment of renal cell carcinoma, favourable healthcare insurance coverage, and impressive healthcare systems customized for the pharmaceutical sector. However, the Asia Pacific market is poised to witness the highest growth in coming years owing to improving healthcare facilities in the region coupled with rising patient pool.
It also highlights RCC drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth.
The later part of the report discusses some of the prominent players in the global renal cell carcinoma drug market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
According to the report “Global Renal Cell Carcinoma Drugs Market 2020”, the renal cell carcinoma drugs market is anticipated to cross US$ 4 Billion by 2020. The report provides a detailed analysis of the market for these drugs. The report provides the current and forecasted market for renal cell carcinoma drugs.
Moreover, the report provides information and revenues of the major branded drugs in the market for this disease. The segmentation of renal cell carcinoma drugs market has been done in the report on the basis of different geographical regions. North America is accounted for the largest share of the renal cell carcinoma market. This high share was attributed to colossal patient pool, large number of commercially available drugs for the treatment of renal cell carcinoma, favourable healthcare insurance coverage, and impressive healthcare systems customized for the pharmaceutical sector. However, the Asia Pacific market is poised to witness the highest growth in coming years owing to improving healthcare facilities in the region coupled with rising patient pool.
It also highlights RCC drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth.
The later part of the report discusses some of the prominent players in the global renal cell carcinoma drug market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. RENAL CELL CARCINOMA - AN INTRODUCTION
4. DRIVERS AND CHALLENGES
4.1 Drivers
4.1.1 Increasing Geriatric Population
4.1.2 Quick Diagnosis with Modern Imaging Techniques
4.1.3 Increasing Risk from Lifestyle Related Factors
4.1.4 Grants and Tax Credits
4.2 Challenges
4.2.1 High Cost
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Rising Patent Cliff
5. RENAL CELL CARCINOMA DRUGS MARKET OVERVIEW
6. MAJOR BRANDED DRUGS
6.1 Sutent
6.2 Votrient
6.3 Afinitor
6.4 Nexavar
6.5 Inlyta
6.6 Avastin
6.7 Proleukin
6.8 Torisel
6.9 Opdivo
7. MARKET SEGMENTATION BY GEOGRAPHY
7.1 North America
7.2 Europe
7.3 Asia-Pacific
8. RENAL CELL CARCINOMA DRUGS PIPELINE
9. TRENDS AND DEVELOPMENTS
9.1 Positive Outcomes from Clinical Trials Driving RCC Market
9.2 ADCs - A Novel Treatment Option for RCC
10. MERGERS AND ACQUISITIONS
11. COMPETITIVE LANDSCAPE
12. KEY PLAYERS ANALYSIS
12.1 Pfizer Inc.
12.2 F.Hoffmann-La Roche AG
12.3 Novartis
12.4 GlaxoSmithKline
12.5 Bayer AG
12.6 Bristol-Myers Squibb
12.7 Merck & Co., Inc.
12.8 AstraZeneca
12.9 Eli Lilly & Co.
12.10 Amgen Inc.
2. RESEARCH METHODOLOGY
3. RENAL CELL CARCINOMA - AN INTRODUCTION
4. DRIVERS AND CHALLENGES
4.1 Drivers
4.1.1 Increasing Geriatric Population
4.1.2 Quick Diagnosis with Modern Imaging Techniques
4.1.3 Increasing Risk from Lifestyle Related Factors
4.1.4 Grants and Tax Credits
4.2 Challenges
4.2.1 High Cost
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Rising Patent Cliff
5. RENAL CELL CARCINOMA DRUGS MARKET OVERVIEW
6. MAJOR BRANDED DRUGS
6.1 Sutent
6.2 Votrient
6.3 Afinitor
6.4 Nexavar
6.5 Inlyta
6.6 Avastin
6.7 Proleukin
6.8 Torisel
6.9 Opdivo
7. MARKET SEGMENTATION BY GEOGRAPHY
7.1 North America
7.2 Europe
7.3 Asia-Pacific
8. RENAL CELL CARCINOMA DRUGS PIPELINE
9. TRENDS AND DEVELOPMENTS
9.1 Positive Outcomes from Clinical Trials Driving RCC Market
9.2 ADCs - A Novel Treatment Option for RCC
10. MERGERS AND ACQUISITIONS
11. COMPETITIVE LANDSCAPE
12. KEY PLAYERS ANALYSIS
12.1 Pfizer Inc.
12.2 F.Hoffmann-La Roche AG
12.3 Novartis
12.4 GlaxoSmithKline
12.5 Bayer AG
12.6 Bristol-Myers Squibb
12.7 Merck & Co., Inc.
12.8 AstraZeneca
12.9 Eli Lilly & Co.
12.10 Amgen Inc.
LIST OF FIGURES:
Figure 4-1: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 6-1: Sutent - Global Revenue (Billion US$), 2011-2014
Figure 6-2: Votrient - Global Revenue (Billion US$), 2011-2014
Figure 6-3: Afinitor - Global Revenue (Billion US$), 2011-2014
Figure 6-4: Nexavar - Global Revenue (Billion US$), 2011-2014
Figure 6-5: Inlyta - Global Revenue (Billion US$), 2012-2014
Figure 6-6: Avastin - Global Revenue (Billion US$), 2011-2014
Figure 6-7: Proleukin - Global Revenue (Billion US$), 2012-2014
Figure 6-8: Torisel - Global Revenue (Billion US$), 2012 & 2013
Figure 7-1: Global - Renal Carcinoma Drugs Market by Geographies (%), 2015
Figure 7-2: North America - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-3: Europe - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-4: Asia-Pacific - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 11-1: Global - Share of Major Players in Renal Cell Carcinoma Drugs Market (%), 2015
Figure 12-1: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche - Breakup of Pharmaceutical Division Revenue by Geographies (%), 2015
Figure 12-3: Novartis - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Bayer AG - Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb - Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: AstraZeneca - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Eli Lilly and Company - Breakup of Revenue by Geographies (%), 2014
Figure 12-10: Amgen Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 4-1: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 6-1: Sutent - Global Revenue (Billion US$), 2011-2014
Figure 6-2: Votrient - Global Revenue (Billion US$), 2011-2014
Figure 6-3: Afinitor - Global Revenue (Billion US$), 2011-2014
Figure 6-4: Nexavar - Global Revenue (Billion US$), 2011-2014
Figure 6-5: Inlyta - Global Revenue (Billion US$), 2012-2014
Figure 6-6: Avastin - Global Revenue (Billion US$), 2011-2014
Figure 6-7: Proleukin - Global Revenue (Billion US$), 2012-2014
Figure 6-8: Torisel - Global Revenue (Billion US$), 2012 & 2013
Figure 7-1: Global - Renal Carcinoma Drugs Market by Geographies (%), 2015
Figure 7-2: North America - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-3: Europe - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-4: Asia-Pacific - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 11-1: Global - Share of Major Players in Renal Cell Carcinoma Drugs Market (%), 2015
Figure 12-1: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche - Breakup of Pharmaceutical Division Revenue by Geographies (%), 2015
Figure 12-3: Novartis - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Bayer AG - Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb - Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: AstraZeneca - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Eli Lilly and Company - Breakup of Revenue by Geographies (%), 2014
Figure 12-10: Amgen Inc. - Breakup of Revenue by Geographies (%), 2014
LIST OF TABLES:
Table 8-1: Renal Cell Carcinoma Drugs Pipeline
Table 10-1: Mergers & Acquisitions in Renal Cell Carcinoma Drugs Market, 2013-2016
Table 11-1: Global - Major Renal Cell Carcinoma Drugs
Table 12-1: Pfizer Inc - Revenues by Business Segment (Billion US$), 2012, 2013 & 2014
Table 12-2: Pfizer Inc - Commercialized Renal Cell Carcinoma Drugs
Table 12-3: Pfizer Inc - Renal Cell Carcinoma Drugs Pipeline
Table 12-4: Roche - Revenue by Business Segments (Billion US$), 2013, 2014 & 2015
Table 12-5: Roche - Commercialized Renal Cell Carcinoma Drugs
Table 12-6: Roche - Renal Cell Carcinoma Drug in Pipeline
Table 12-7: Novartis - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-8: Novartis - Commercialized Renal Cell Carcinoma Drugs
Table 12-9: Novartis - Renal Cell Carcinoma Drugs Pipeline
Table 12-10: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-11: GlaxoSmithKline - Commercialized Renal Cell Carcinoma Drugs
Table 12-12: GlaxoSmithKline - Renal Cell Carcinoma Drugs Pipeline
Table 12-13: Bayer AG - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-14: Bayer AG - Commercialized Renal Cell Carcinoma Drugs
Table 12-15: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-16: Bristol Myers Squibb - Commercialized Renal Cell Carcinoma Drugs
Table 12-17: Bristol Myers Squibb - Renal Cell Carcinoma Drugs Pipeline
Table 12-18: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-19: Merck & Co., Inc. - Renal Cell Carcinoma Drugs Pipeline
Table 12-20: AstraZeneca - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-21: AstraZeneca - Renal Cell Carcinoma Drugs Pipeline
Table 12-22: Eli Lilly & Co. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-23: Eli Lilly & Co. - Renal Cell Carcinoma Drugs Pipeline
Table 12-24: Amgen Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-25: Amgen Inc. - Renal Cell Carcinoma Drugs Pipeline
Table 8-1: Renal Cell Carcinoma Drugs Pipeline
Table 10-1: Mergers & Acquisitions in Renal Cell Carcinoma Drugs Market, 2013-2016
Table 11-1: Global - Major Renal Cell Carcinoma Drugs
Table 12-1: Pfizer Inc - Revenues by Business Segment (Billion US$), 2012, 2013 & 2014
Table 12-2: Pfizer Inc - Commercialized Renal Cell Carcinoma Drugs
Table 12-3: Pfizer Inc - Renal Cell Carcinoma Drugs Pipeline
Table 12-4: Roche - Revenue by Business Segments (Billion US$), 2013, 2014 & 2015
Table 12-5: Roche - Commercialized Renal Cell Carcinoma Drugs
Table 12-6: Roche - Renal Cell Carcinoma Drug in Pipeline
Table 12-7: Novartis - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-8: Novartis - Commercialized Renal Cell Carcinoma Drugs
Table 12-9: Novartis - Renal Cell Carcinoma Drugs Pipeline
Table 12-10: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-11: GlaxoSmithKline - Commercialized Renal Cell Carcinoma Drugs
Table 12-12: GlaxoSmithKline - Renal Cell Carcinoma Drugs Pipeline
Table 12-13: Bayer AG - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-14: Bayer AG - Commercialized Renal Cell Carcinoma Drugs
Table 12-15: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-16: Bristol Myers Squibb - Commercialized Renal Cell Carcinoma Drugs
Table 12-17: Bristol Myers Squibb - Renal Cell Carcinoma Drugs Pipeline
Table 12-18: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-19: Merck & Co., Inc. - Renal Cell Carcinoma Drugs Pipeline
Table 12-20: AstraZeneca - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-21: AstraZeneca - Renal Cell Carcinoma Drugs Pipeline
Table 12-22: Eli Lilly & Co. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-23: Eli Lilly & Co. - Renal Cell Carcinoma Drugs Pipeline
Table 12-24: Amgen Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-25: Amgen Inc. - Renal Cell Carcinoma Drugs Pipeline
